Global Myeloproliferative Neoplasm Drugs Market to Surpass US$ 10,966.8 Million by 2027, Says Coherent Market Insights (CMI)
Washingtoner/10101104

Trending...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027).

Key Trends and Analysis:

The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.

Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).

Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.

More on Washingtoner
Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930

Key Market Takeaways:

The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.

Competitive Landscape:

Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals

Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930

Market Segmentation:
  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
    • Demethylation Agents
    • Tyrosine kinase Inhibitor
    • Multikinase Inhibitors
    • JAK2 Inhibitor
    • Others
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication:
    • Ph+ Chronic myelogenous leukemia (CML)
    • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Myeloproliferative Neoplasm Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

More on Washingtoner
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Washingtoner
_catLbl0 _catLbl1